Breast MR spectroscopy reduces false positives

Article

Spectroscopy can help reduce breast MRI false positives, which tend to increase at various stages of the menstrual cycle, according to researchers at Memorial Sloan-Kettering Cancer Center.

Spectroscopy can help reduce breast MRI false positives, which tend to increase at various stages of the menstrual cycle, according to researchers at Memorial Sloan-Kettering Cancer Center.

Researchers led by Dr. Lia Bartella performed prospective MRS scans on 27 high-risk subjects undergoing screening breast MRI. Eight were in different stages of their menstrual cycle. The investigators defined a positive MRS as having a choline peak greater than or equal to 2.

The protocol was tested in healthy breast tissue contralateral to the diseased breast. Researchers found that choline did not vary in any of the women and ruled out false positives regardless of a subject's menstrual cycle stage. The result is confidence in true-positive and true-negative findings when they perform MRS in the breast, Bartella said at the 2005 RSNA meeting.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.